This page contains a Flash digital edition of a book.
Our work on oral cancer has informed Department of Health work on the feasibility of cancer screening. Researchers from the School have prepared the UK National Screening Committee and British Dental Association guidelines on prevention and early detection of oral cancer in primary care. Laboratory research has led to a greater understanding of the cell biology of oral cancer and the role of innate immunity in cancer and oral mucosal diseases.


Our dental public health research is wide-ranging and life-changing. An outstanding example is our research into children and young people’s oral health using a combination of clinical and social research strategies to give children an active voice on oral health, to develop a full understanding of the impact of oral health and related conditions on children and their families, and to measure the impact of oral health on children's quality of life.


Our partners


Our research is funded by the major UK research councils and charities including the MRC, BBSRC, EPSRC, Yorkshire Cancer Research and Wellcome Trust, as well as by NIHR and NIH (USA). There is a seamless collaboration between the University and hospital research programmes with a co-ordinated programme of clinical research into oral health. This includes research into community, individual and disease factors with evaluation of diagnostics and outcomes of new interventions (a ‘community to clinical’ concept).


Across the University, we work with ScHARR, Medicine, Chemistry, Chemical and Process Engineering, Molecular Biology and Biotechnology, the Tissue Engineering Research cluster and the Yorkshire Biomaterials Network. Work includes development of new synthetic materials, biosensors to detect infection and the improvement of community dental health.


For more information about our research: www.sheffield.ac.uk/dentalschool/research


–––


SPOTLIGHT ON


Professor Fiona Boissonade –––


Chronic pain, including that from the orofacial region,


represents a major public health problem, impacting on health, quality of life and the economy. With the lack of reliable


treatment, this is an area of high unmet clinical need.


Professor Boissonade’s group has a major research interest in the


mechanisms of altered neuronal excitability that occur under the


pathological conditions of nerve injury and inflammation, and which


contribute to the development of chronic pain.


Much of this work has been done at the academic–industrial interface.


In the recent Research Assessment Exercise


70%


of our research was graded as ‘world leading’ or ‘internationally excellent’


Professor Boissonade’s collaborations with GlaxoSmithKline, Pfizer and Eli Lilly focus on the development of novel analgesics based on the


identification of a range of regulators of neuronal excitability. In addition,


ongoing projects with Renovo plc are directed towards improvement of nerve regeneration following injury.


15


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40